Molecular Imaging in Cardiology Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Molecular Imaging in Cardiology. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Molecular Imaging in Cardiology Indian Medical PG Question 1: Best way to localize extra-adrenal pheochromocytoma:
- A. X-ray
- B. Clinical examination
- C. VMA excretion
- D. Nuclear medicine scan (MIBG scan) (Correct Answer)
Molecular Imaging in Cardiology Explanation: ***Nuclear medicine scan (MIBG scan)***
- **Iodine-131-metaiodobenzylguanidine (MIBG) scan** is the imaging modality of choice for localizing extra-adrenal pheochromocytomas due to its high specificity for **neuroendocrine tumors** like pheochromocytomas and paragangliomas.
- MIBG is structurally similar to **norepinephrine** and is actively taken up by adrenergic neurons, allowing visualization of hypersecreting chromaffin cells wherever they are located in the body.
*X-ray*
- **X-rays** provide limited soft tissue detail and are generally not useful for localizing pheochromocytomas, especially extra-adrenal ones.
- They may show calcifications in some tumors but lack the sensitivity and specificity needed for definitive localization.
*Clinical examination*
- A **clinical examination** can identify signs and symptoms suggestive of pheochromocytoma (e.g., hypertension, palpitations, sweating) but cannot localize the tumor itself.
- Localization requires **imaging studies** due to the variable and often deep-seated location of these tumors.
*VMA excretion*
- **Vanillylmandelic acid (VMA) excretion** is a biochemical test used to diagnose pheochromocytoma by measuring catecholamine metabolites in urine.
- While it confirms the presence of a catecholamine-secreting tumor, it provides **no information about the tumor's location**.
Molecular Imaging in Cardiology Indian Medical PG Question 2: The most sensitive and practical technique for detection of myocardial ischemia in the perioperative period is -
- A. Direct measurement of end diastolic pressure
- B. Radio labeled lactate determination
- C. Magnetic Resonance Spectroscopy
- D. Regional wall motion abnormality detected with the help of 2D transoesophageal echocardiography (Correct Answer)
Molecular Imaging in Cardiology Explanation: ***Regional wall motion abnormality detected with the help of 2D transesophageal echocardiography***
- **Transesophageal echocardiography (TEE)** provides high-resolution images of the heart, allowing for the sensitive detection of **regional wall motion abnormalities (RWMA)**, an early and practical indicator of myocardial ischemia in the perioperative setting.
- The development of new or worsening RWMA is often the **first sign of ischemia**, preceding ECG changes or hemodynamic alterations, making it a highly sensitive and clinically useful tool.
*Direct measurement of end-diastolic pressure*
- While an elevated **end-diastolic pressure** can indicate ventricular dysfunction, it is an **indirect sign** and not specific enough for early myocardial ischemia detection.
- This measurement often requires invasive monitoring, which is less practical for routine detection compared to TEE.
*Radio-labeled lactate determination*
- **Lactate production** can increase in ischemic tissue, but its detection is a **biochemical marker** that typically lags behind the onset of ischemia.
- This technique is generally **research-oriented** and not a practical, bedside method for rapid perioperative ischemia detection.
*Magnetic Resonance Spectroscopy*
- **Magnetic Resonance Spectroscopy (MRS)** can provide detailed metabolic information about tissue, including changes related to ischemia.
- However, it is a **complex, time-consuming, and expensive imaging modality** that is not practical for routine, real-time perioperative monitoring of myocardial ischemia.
Molecular Imaging in Cardiology Indian Medical PG Question 3: For pericardial calcifications, which is the best investigation?
- A. Ultrasound
- B. CT scan (Correct Answer)
- C. MRI
- D. Transesophageal echocardiography
Molecular Imaging in Cardiology Explanation: ***Correct: CT scan***
- **CT scans** are highly sensitive and specific for detecting **pericardial calcifications** due to their excellent spatial resolution and ability to measure calcium density (Hounsfield units).
- They provide detailed anatomical information about the **pericardium** and can accurately map the extent, location, and thickness of calcified areas.
- **CT is the gold standard** for detecting and quantifying pericardial calcification, particularly in constrictive pericarditis.
*Incorrect: Ultrasound*
- While ultrasound (echocardiography) can visualize the pericardium and may detect calcifications, its ability to definitively identify and characterize **calcifications** is limited compared to CT.
- **Acoustic shadowing** from calcifications can obscure underlying structures, making a precise assessment challenging.
- Useful for detecting pericardial effusion and thickening, but not optimal for calcification assessment.
*Incorrect: MRI*
- **MRI excels** in visualizing soft tissues, pericardial inflammation, and fluid collections, but it is **poor at detecting calcium**.
- Calcifications typically appear as signal voids (black) on MRI, making it difficult to differentiate them from other structures, air, or motion artifacts.
- MRI is valuable for assessing pericardial inflammation and constriction but not the preferred method for calcification.
*Incorrect: Transesophageal echocardiography*
- TEE offers high-resolution images of cardiac structures and is primarily used for assessing valve function, intracardiac masses, endocarditis, and aortic pathology.
- Its utility in detecting and characterizing **pericardial calcifications** is limited compared to CT, especially for diffuse or subtle calcifications.
- The pericardium is not optimally visualized with TEE compared to transthoracic echocardiography.
Molecular Imaging in Cardiology Indian Medical PG Question 4: Which imaging modality delivers the highest dose of radiation?
- A. Cardiac perfusion scan (Correct Answer)
- B. CT scan of the chest
- C. Mammogram
- D. CT scan of the brain
Molecular Imaging in Cardiology Explanation: ***Cardiac perfusion scan***
- A **cardiac perfusion scan (nuclear cardiology)** involves the administration of a radioactive tracer, and the radiation dose can be significant due to the nature and energy of the isotopes used.
- While varying, the effective dose for these scans can range from **10 to 30 mSv**, placing it among some of the highest radiation exposures from medical imaging.
*CT scan of the chest*
- A **CT scan of the chest** provides a relatively high radiation dose compared to plain X-rays, typically ranging from **5 to 7 mSv**.
- This is generally lower than some nuclear medicine studies, particularly complex or prolonged cardiac perfusion scans.
*Mammogram*
- A **mammogram** involves a relatively low dose of radiation, typically in the range of **0.2 to 0.7 mSv**.
- Its objective is to image the breast tissue with minimal exposure, making it one of the lower-dose imaging modalities available.
*CT scan of the brain*
- A **CT scan of the brain** usually delivers a moderate radiation dose, estimated to be around **1 to 2 mSv**.
- This is often less than a chest CT due to the smaller volume and different shielding considerations, and significantly less than a cardiac perfusion scan.
Molecular Imaging in Cardiology Indian Medical PG Question 5: A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?
- A. 64Cu for longer imaging window despite inferior image quality
- B. 64Cu because shorter positron range improves resolution
- C. 18F for better spatial resolution despite requiring on-site cyclotron (Correct Answer)
- D. 18F because longer half-life allows delayed imaging
Molecular Imaging in Cardiology Explanation: ***18F for better spatial resolution despite requiring on-site cyclotron***
- **18F** has a shorter **positron range** compared to **64Cu**, which minimizes the distance the positron travels before annihilation, leading to superior **spatial resolution**.
- While it necessitates proximity to a **cyclotron** due to a 110-minute half-life, this timeframe is sufficient for most **hypoxia imaging** tracers to reach a high **target-to-background ratio**.
*64Cu for longer imaging window despite inferior image quality*
- **64Cu** provides a longer imaging window due to its **12.7-hour half-life**, but its longer **positron range** leads to increased **blurring** and poorer resolution.
- For diagnostic **tumor hypoxia**, the extra-long window is often unnecessary and leads to a higher **absorbed radiation dose** for the patient.
*64Cu because shorter positron range improves resolution*
- This statement is factually incorrect as **64Cu** actually has a significantly longer **effective positron range** than **18F**.
- Higher **energy positrons** travel further in tissue, which degrades the **image quality** by misplacing the site of annihilation relative to the source.
*18F because longer half-life allows delayed imaging*
- This is incorrect as **18F** has a much shorter half-life (**110 minutes**) compared to the **12.7 hours** of **64Cu**.
- The shorter half-life of **18F** prevents very late delayed imaging but helps in keeping the total **patient radiation exposure** lower.
Molecular Imaging in Cardiology Indian Medical PG Question 6: In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?
- A. 18F-PSMA with 4 hour delayed imaging
- B. 68Ga-PSMA with 3 hour uptake time without furosemide
- C. 68Ga-PSMA with 1 hour uptake time and furosemide administration (Correct Answer)
- D. 18F-PSMA with 30 minutes uptake time and forced hydration
Molecular Imaging in Cardiology Explanation: ***68Ga-PSMA with 1 hour uptake time and furosemide administration***
- An **uptake time of 60 minutes** is the standard for **68Ga-PSMA**, providing an optimal **target-to-background ratio** (TBR) while maintaining efficient clinical workflow.
- The administration of **furosemide** (a loop diuretic) promotes **urinary washout** of the tracer, reducing interfering **bladder activity** and lowering the radiation dose to the urinary tract.
*18F-PSMA with 4 hour delayed imaging*
- While **18F-labeled tracers** have a longer half-life, a 4-hour delay is excessive and leads to significant **decay of activity**, potentially requiring higher initial doses and increasing **radiation exposure**.
- Such long delays are not practical for routine clinical protocols and do not provide a significant clinical advantage over standard 1-2 hour imaging for most **PSMA** ligands.
*68Ga-PSMA with 3 hour uptake time without furosemide*
- **68Ga** has a short physical half-life (68 minutes), so a 3-hour wait significantly reduces the **count rate**, leading to poor **image quality** due to increased noise.
- Omitting **furosemide** results in high tracer concentration in the **bladder**, which can obscure local recurrence in the **prostate bed** or nearby pelvic lymph nodes via **halo artifacts**.
*18F-PSMA with 30 minutes uptake time and forced hydration*
- A **30-minute uptake time** is generally insufficient for optimal **tracer internalization** into prostate cancer cells, resulting in a lower **tumor-to-background ratio**.
- Although **forced hydration** helps, it is less effective than **furosemide** at rapidly clearing the high-intensity tracer from the **distal ureters** and bladder during the peak imaging window.
Molecular Imaging in Cardiology Indian Medical PG Question 7: A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?
- A. Progressive disease requiring treatment escalation
- B. Treatment-induced necrosis with favorable prognosis (Correct Answer)
- C. Flare phenomenon indicating treatment response
- D. Infection complicating the metastasis
Molecular Imaging in Cardiology Explanation: ***Treatment-induced necrosis with favorable prognosis***
- A decrease in **SUVmax** indicates a reduction in **metabolic activity** and viable tumor cells, even if the physical dimensions of the lesion increase.
- The increase in size is often due to **necrosis, edema, or inflammation** following successful therapy, representing a favorable response to treatment rather than failure.
*Progressive disease requiring treatment escalation*
- Progressive disease typically presents with an **increase in both size and SUVmax**, reflecting active metabolic growth of the tumor.
- Relying solely on **CT size measurements** (like RECIST criteria) can be misleading when PET shows a significant drop in **glucose metabolism**.
*Flare phenomenon indicating treatment response*
- The **flare phenomenon** usually refers to a transient *increase* in tracer uptake (SUVmax) shortly after starting treatment (e.g., bone flare in breast cancer patients).
- In this scenario, the activity **decreased over 3 months**, which is more consistent with a sustained metabolic response than a metabolic flare.
*Infection complicating the metastasis*
- An active infection or inflammatory process would typically lead to an **increase in SUVmax** due to high metabolic activity in activated white blood cells.
- There is no clinical information provided to suggest systemic **fever or local infection**, and the metabolic trend (decreasing SUV) contradicts an inflammatory spike.
Molecular Imaging in Cardiology Indian Medical PG Question 8: A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?
- A. High grade aggressive tumor
- B. Well-differentiated slow-growing tumor (Correct Answer)
- C. Necrotic tumor with inflammation
- D. False positive DOTATATE scan
Molecular Imaging in Cardiology Explanation: ***Well-differentiated slow-growing tumor***
- High **DOTATATE uptake** indicates dense expression of **somatostatin receptors (SSTRs)**, which is a hallmark of well-differentiated neuroendocrine tumors.
- Low **FDG uptake** (low SUVmax) reflects a low rate of glucose metabolism, signifying a **low-grade (G1/G2)** tumor with a slow proliferation rate.
*High grade aggressive tumor*
- Aggressive, high-grade neuroendocrine carcinomas (G3) typically show high **FDG avidity** because they rely heavily on glycolysis for energy.
- These tumors often lose their **somatostatin receptor expression**, leading to low or absent uptake on a **DOTATATE scan**.
*Necrotic tumor with inflammation*
- **Necrosis** generally presents as a photopenic (cold) area in the center of a lesion on PET imaging, not intense DOTATATE uptake.
- **Inflammation** would typically result in increased **FDG uptake** due to high metabolic activity in activated leukocytes, rather than isolated high DOTATATE avidity.
*False positive DOTATATE scan*
- Intense uptake with an **SUVmax of 45** is highly specific for SSTR-rich tissues and is considered diagnostic for neuroendocrine pathology in this clinical context.
- A **gastrinoma** is a known neuroendocrine tumor (NET) that consistently expresses these receptors, making a false positive highly unlikely.
Molecular Imaging in Cardiology Indian Medical PG Question 9: A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?
- A. Administer insulin and delay scan until glucose <150 mg/dL (Correct Answer)
- B. Double the FDG dose to compensate
- C. Cancel scan and reschedule after glucose control
- D. Proceed immediately with scanning
Molecular Imaging in Cardiology Explanation: ***Administer insulin and delay scan until glucose <150 mg/dL***
- **Hyperglycemia** causes competitive inhibition of **FDG uptake** in tumor cells, as glucose and FDG compete for the same **GLUT transporters**.
- Administering insulin lowers blood glucose to an acceptable range (ideally **<150 mg/dL**) to ensure optimal **diagnostic accuracy** and image quality, though scanning should occur at least 2 hours after insulin administration to avoid muscle uptake.
*Double the FDG dose to compensate*
- Increasing the **FDG dose** does not bypass the competitive inhibition caused by serum glucose and will only increase **radiation exposure** unnecessarily.
- High blood sugar levels will still prioritize **native glucose** over FDG into cells, resulting in a poor **signal-to-noise ratio**.
*Cancel scan and reschedule after glucose control*
- While long-term control is ideal, acute management with **short-acting insulin** allows the scan to proceed on the same day once levels fall below the threshold.
- Rescheduling is only necessary if the patient's **blood glucose** remains persistently high and unresponsive to immediate clinical intervention.
*Proceed immediately with scanning*
- Scanning with a glucose level of **220 mg/dL** leads to poor image quality and potential **false-negative** results due to diminished tracer uptake in the lymphoma.
- Elevated **endogenous glucose** saturates the receptors, preventing the radioactive tracer from adequately labeling the **metabolically active** tumor sites.
Molecular Imaging in Cardiology Indian Medical PG Question 10: A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?
- A. Both primary and nodal metastasis (Correct Answer)
- B. Primary tumor with false positive node
- C. Dual primary malignancies
- D. Primary tumor only, node is inflammatory
Molecular Imaging in Cardiology Explanation: ***Both primary and nodal metastasis***
- In lung cancer staging, a **Standardized Uptake Value (SUVmax)** greater than 2.5 in mediastinal lymph nodes is highly suspicious for **metastatic involvement**.
- The node's SUVmax of 4.2 relative to the primary tumor's high uptake (8.5) strongly indicates **metabolically active disease** at both the primary and nodal sites.
*Primary tumor with false positive node*
- **False positives** on PET often occur due to granulomatous disease or infection, but an SUVmax of 4.2 in a known cancer context is more likely **metastatic**.
- Without history of **sarcoidosis** or active infection, the metabolic activity in the lymphatic basin of the primary tumor is considered malignant until proven otherwise.
*Dual primary malignancies*
- Two separate primary malignancies would typically involve different anatomical sites or different **histological features**, rather than a primary and its draining node.
- The presence of a mediastinal node in a patient with a known lung mass is the classic presentation of **regional spread** (N staging), not a second primary site.
*Primary tumor only, node is inflammatory*
- While inflammation can cause **FDG avidity**, an SUVmax of 4.2 is significantly high and less typical for purely reactive or **incidental inflammatory** nodes.
- Relying on an inflammatory interpretation without biopsy would risk **understaging** the patient's lung cancer, as the node meets the metabolic criteria for malignancy.
More Molecular Imaging in Cardiology Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
